• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ORTHO-CLINICAL DIAGNOSTICS, INC. VITROS IMMUNODIAGNOSTIC PRODUCTS NT PROBNP REAGENT PACK; IN-VITRO DIAGNOSTICS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ORTHO-CLINICAL DIAGNOSTICS, INC. VITROS IMMUNODIAGNOSTIC PRODUCTS NT PROBNP REAGENT PACK; IN-VITRO DIAGNOSTICS Back to Search Results
Model Number 6192255
Device Problem High Test Results (2457)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 06/03/2023
Event Type  malfunction  
Event Description
A customer contacted the ortho clinical diagnostics (ortho) technical solution center (tsc) to report higher than expected vitros nt pro-bnp ii results were obtained from non-vitros biorad qc fluids and numerous patient samples using vitros immunodiagnostics products nt pro-bnp ii reagent lots 0091, 0125 and 0130 in combination with a vitros 5600 integrated system.Vitros nbnp2 lot 0091 results: biorad level 1 quality control results of 1574, 1573, 1574, 1576, 1572, 1576 and 1575 pg/ml vs.Expected result of 50.6 pg/ml.Biorad level 3 quality control results of 4161, 4067, 4145, 4104 and 4096 pg/ml vs.Expected result of 2830 pg/ml.Patient 2 result of 1560 pg/ml vs.Expected result of 38 pg/ml.Patient 3 result of 1770 pg/ml vs.Expected result of 253 pg/ml.Patient 5 result of 1630 pg/ml vs.Expected result of 106 pg/ml.Patient 7 result of 2260 pg/ml vs.Expected result of 710 pg/ml.Patient 8 result of 1560 pg/ml vs.Expected result of 39 pg/ml.Vitros nbnp2 lot 0125 results: biorad level 1 quality control results of 1573 pg/ml vs.Expected result of 50.6 pg/ml.Biorad level 3 quality control results of 4073 pg/ml vs.Expected result of 2830 pg/ml.Vitros nbnp2 lot 0130 results: biorad level 1 quality control results of 1569 pg/ml vs.Expected result of 50.6 pg/ml.Biorad level 3 quality control results of 4125 pg/ml vs.Expected result of 2830 pg/ml.Biased results of the magnitude and direction observed may lead to inappropriate physician action if they were to occur undetected.The higher than expected nt pro-bnp ii quality control results were from non-patient fluids and were not reported from the laboratory.However, patient samples were processed when the qc fluids were out of range and results for these samples were reported from the laboratory.Corrected reports were later issued for the samples reported and ortho has not been made aware of any treatment administered, altered or stopped based on the reported results.Ortho has not been made aware of any allegation of patient harm as a result of this event.This report is number three of three mdr¿s for this event.Three 3500a forms are being submitted for this event as three devices were involved.This report corresponds to ortho clinical diagnostics inc (ortho) complaint number (b)(4), (b)(4), (b)(4) and reportability assessment (b)(4).
 
Manufacturer Narrative
The investigation determined that higher than expected vitros nt pro-bnp ii results were obtained from non-vitros biorad qc fluids and numerous patient samples using vitros immunodiagnostics products nt pro-bnp ii reagent lots 0091, 0125 and 0130 in combination with a vitros 5600 integrated system.The cause of the higher than expected biorad qc fluid results and patient sample results has been established to be user error.At some point between 01 june 2023 and 02 june 2023 the customer altered the slope and intercept parameters causing the significant bias in vitros nbnp2 results obtained until the slope and intercept parameters were reset to default settings on (b)(6) 2023.There is no indication that the vitros 5600 integrated system or the vitros nbnp2 reagents malfunctioned in any way as all other biorad qc fluids tested were performing acceptably and patient samples predicted as expected when the slope and intercept parameters were set at default levels.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VITROS IMMUNODIAGNOSTIC PRODUCTS NT PROBNP REAGENT PACK
Type of Device
IN-VITRO DIAGNOSTICS
Manufacturer (Section D)
ORTHO-CLINICAL DIAGNOSTICS, INC.
100 indigo creek drive
rochester NY 14626
Manufacturer (Section G)
ORTHO-CLINICAL DIAGNOSTICS
felindre meadows
pencoed
bridgend CF35 5PZ
UK   CF35 5PZ
Manufacturer Contact
laurie o'riordan
microtyping systems
1295 southwest 29th avenue
pompano beach, FL 33069
9549709500
MDR Report Key17219456
MDR Text Key318049798
Report Number3007111389-2023-00110
Device Sequence Number1
Product Code NBC
UDI-Device Identifier10758750033300
UDI-Public10758750033300
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 06/28/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date10/12/2023
Device Model Number6192255
Device Catalogue Number6192255
Device Lot Number0125
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 06/04/2023
Initial Date FDA Received06/28/2023
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured04/17/2023
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-